Abstract
Context: Although GH has been used to treat short stature in GH deficiency (GHD) and other conditions for more than 40 yr, criteria for satisfactorily defining targets for GH responsiveness have never been developed. Objective: The objective of this study was to present the first-year growth expressed as height velocity (HV) for prepubertal boys and girls with idiopathic GHD, organic GHD, idiopathic short stature, or Turner syndrome from Genentech's National Cooperative Growth Study to derive age-specific targets for GH responsiveness for each etiology and gender. Design and Population: Using data from the National Cooperative Growth Study, we constructed curves of response to GH during the first year of treatment with standard daily doses in naive-totreatment prepubertal children with idiopathic GHD (2323 males, 842 females), organic GHD (582 males, 387 females), idiopathic short stature (1392 males, 465 females), or Turner syndrome (1367 females). Main Outcome Measure: For each category, mean pretreatment and mean ±1 and ±2 SD for the first-year HV on GH were assessed. Mean and mean ± 1 SD for HV were plotted vs. age at baseline (initiation of GH treatment) and compared with mean pretreatment HV. Results: HV plots for each category as a factor of age at baseline are presented. Mean - 2 SD HV plots approximated the pretreatment HV. Conclusion: Using baseline age- and gender-specific targets will assist clinicians in assessing a patient's first-year growth response. We propose that HV below the mean - 1 SD on these plots be considered a "poor" response. These curvesmaybe used to identify patients who may benefit from GH dose adjustment, to assess compliance issues, or to challenge the original diagnosis.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 352-357 |
| Number of pages | 6 |
| Journal | Journal of Clinical Endocrinology and Metabolism |
| Volume | 93 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2008 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Biochemistry
- Endocrinology, Diabetes and Metabolism
Cite this
Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children. / Bakker, Bert; Frane, James; Anhalt, Henry; Lippe, Barbara; Rosenfeld, Ronald (Ron).
In: Journal of Clinical Endocrinology and Metabolism, Vol. 93, No. 2, 02.2008, p. 352-357.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children
AU - Bakker, Bert
AU - Frane, James
AU - Anhalt, Henry
AU - Lippe, Barbara
AU - Rosenfeld, Ronald (Ron)
PY - 2008/2
Y1 - 2008/2
N2 - Context: Although GH has been used to treat short stature in GH deficiency (GHD) and other conditions for more than 40 yr, criteria for satisfactorily defining targets for GH responsiveness have never been developed. Objective: The objective of this study was to present the first-year growth expressed as height velocity (HV) for prepubertal boys and girls with idiopathic GHD, organic GHD, idiopathic short stature, or Turner syndrome from Genentech's National Cooperative Growth Study to derive age-specific targets for GH responsiveness for each etiology and gender. Design and Population: Using data from the National Cooperative Growth Study, we constructed curves of response to GH during the first year of treatment with standard daily doses in naive-totreatment prepubertal children with idiopathic GHD (2323 males, 842 females), organic GHD (582 males, 387 females), idiopathic short stature (1392 males, 465 females), or Turner syndrome (1367 females). Main Outcome Measure: For each category, mean pretreatment and mean ±1 and ±2 SD for the first-year HV on GH were assessed. Mean and mean ± 1 SD for HV were plotted vs. age at baseline (initiation of GH treatment) and compared with mean pretreatment HV. Results: HV plots for each category as a factor of age at baseline are presented. Mean - 2 SD HV plots approximated the pretreatment HV. Conclusion: Using baseline age- and gender-specific targets will assist clinicians in assessing a patient's first-year growth response. We propose that HV below the mean - 1 SD on these plots be considered a "poor" response. These curvesmaybe used to identify patients who may benefit from GH dose adjustment, to assess compliance issues, or to challenge the original diagnosis.
AB - Context: Although GH has been used to treat short stature in GH deficiency (GHD) and other conditions for more than 40 yr, criteria for satisfactorily defining targets for GH responsiveness have never been developed. Objective: The objective of this study was to present the first-year growth expressed as height velocity (HV) for prepubertal boys and girls with idiopathic GHD, organic GHD, idiopathic short stature, or Turner syndrome from Genentech's National Cooperative Growth Study to derive age-specific targets for GH responsiveness for each etiology and gender. Design and Population: Using data from the National Cooperative Growth Study, we constructed curves of response to GH during the first year of treatment with standard daily doses in naive-totreatment prepubertal children with idiopathic GHD (2323 males, 842 females), organic GHD (582 males, 387 females), idiopathic short stature (1392 males, 465 females), or Turner syndrome (1367 females). Main Outcome Measure: For each category, mean pretreatment and mean ±1 and ±2 SD for the first-year HV on GH were assessed. Mean and mean ± 1 SD for HV were plotted vs. age at baseline (initiation of GH treatment) and compared with mean pretreatment HV. Results: HV plots for each category as a factor of age at baseline are presented. Mean - 2 SD HV plots approximated the pretreatment HV. Conclusion: Using baseline age- and gender-specific targets will assist clinicians in assessing a patient's first-year growth response. We propose that HV below the mean - 1 SD on these plots be considered a "poor" response. These curvesmaybe used to identify patients who may benefit from GH dose adjustment, to assess compliance issues, or to challenge the original diagnosis.
UR - http://www.scopus.com/inward/record.url?scp=39049171452&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=39049171452&partnerID=8YFLogxK
U2 - 10.1210/jc.2007-1581
DO - 10.1210/jc.2007-1581
M3 - Article
C2 - 18000092
AN - SCOPUS:39049171452
VL - 93
SP - 352
EP - 357
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
SN - 0021-972X
IS - 2
ER -